4.2 GLP-1-based agents The focus of GLP-1RA development has predominantly been on designing GLP-1 derivatives resistant to DPP-4 enzymatic activity and exhibiting slow renal clearance through chemical modification and pharmaceutical formulation
Disease Prevention & Management Beyond reducing the risks of heart disease, GLP-1 RAs have also been explored for prevention and managing: 12 Chronic kidney disease (CKD) Neurological diseases, including Alzheimer's and Parkinson's diseases Non-alcoholic fatty liver disease (NAFLD) Polycystic ovary syndrome (PCOS) And this list is likely just be the beginning, as overweight and obese individuals are at significant risk of many serious health conditions like cancer and depression
As a TEDx speaker and Inc
Phase 2 data showed clinically significant weight loss across all dose arms above 4mg
Step 4: ask your doctor to run a benefits verification Your prescribing physician office can often run a real-time benefits check through their pharmacy benefits management system
And individuals using GLP-1 for reasons beyond weight loss, such as metabolic health optimization or inflammatory conditions, may not need full therapeutic doses